Immatics Biotechnologies Company Insiders

Immatics Biotechnologies Management Team Effectiveness

The company has return on total asset (ROA) of (0.0828) % which means that it has lost $0.0828 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.177) %, meaning that it generated substantial loss on money invested by shareholders. Immatics Biotechnologies' management efficiency ratios could be used to measure how well Immatics Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.18 in 2025. Return On Capital Employed is likely to drop to -0.27 in 2025. At this time, Immatics Biotechnologies' Non Current Assets Total are fairly stable compared to the past year. Other Current Assets is likely to climb to about 21.4 M in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 1.6 M in 2025. Common Stock Shares Outstanding is likely to drop to about 70.8 M in 2025

Immatics Biotechnologies Workforce Comparison

The company has Profit Margin (PM) of (0.48) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.01 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.01.

Immatics Biotechnologies Benchmark Summation

Immatics Biotechnologies Notable Stakeholders

The success or failure of an entity such as Immatics Biotechnologies often depends on how effective the management is. Immatics Biotechnologies management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Immatics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Immatics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Immatics Biotechnologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of immatics biotechnologies GmbH. Check Immatics Biotechnologies' Beneish M Score to see the likelihood of Immatics Biotechnologies' management manipulating its earnings.

When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.